RGLS4326（RG4326）作为首创性microRNA-17抑制剂，通过特异性靶向miR-17调控下游信号通路，在常染色体显性多囊肾病（ADPKD）的病理干预中展现出治疗潜力。

/

-25~-15℃避光保存，有效期3年。

[1] Lee EC, Valencia T, Allerson C, Schairer A, Flaten A, Yheskel M, Kersjes K, Li J, Gatto S, Takhar M, Lockton S, Pavlicek A, Kim M, Chu T, Soriano R, Davis S, Androsavich JR, Sarwary S, Owen T, Kaplan J, Liu K, Jang G, Neben S, Bentley P, Wright T, Patel V. Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148. doi: 10.1038/s41467-019-11918-y. PMID: 31515477; PMCID: PMC6742637.